Rocamed has announced the strategic acquisition of Delmont Imaging, a move the company describes as a “transformative milestone” positioning it as a leading Uro-Gyn medtech specialist.
While full deal terms have not been publicly disclosed, the integration brings together Rocamed’s global urology and laparoscopy portfolio with Delmont Imaging’s CE-certified gynecological endoscopy systems, including hysteroscopes, resectoscopes, and outpatient “see-and-treat” technologies.
Related: Avandra creates medical imaging platform with new acquisitions
The acquisition expands Rocamed’s reach across minimally invasive urology and gynecology, leveraging Delmont’s strong presence in gynecological imaging and outpatient care. Both companies are expected to benefit from shared manufacturing, regulatory, and global distribution strengths; Rocamed already serves more than 65 countries and recently secured private-equity backing from 21 Invest.
Although no formal press release or regulatory filing has been issued, early indications suggest a consolidation strategy aimed at broadening the combined product pipeline and advancing MIS (minimally invasive surgery) solutions for both urology and gynecology. Industry observers now watch for updates on product integration, regulatory transitions, and global rollout as this partnership shapes a potential new chapter in Uro-Gyn care.
